# Contents

## Highlights of This Issue 3717

### SPECIAL FEATURES

#### CCR Translations

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3719</td>
<td>Dual PI3K/mTOR Inhibitors: Does p53 Modulate Response?</td>
<td>Oleksandr Ekshyyan, Arunkumar Anandharaj, and Cherie-Ann O. Nathan</td>
</tr>
<tr>
<td></td>
<td><em>See article, p. 3808</em></td>
<td></td>
</tr>
</tbody>
</table>

#### CCR Perspectives in Drug Approval

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3722</td>
<td>Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals</td>
<td>Michael B. Shea, Samantha A. Roberts, Jessica C. Walrath, Jeff D. Allen, and Ellen V. Sigal</td>
</tr>
</tbody>
</table>

#### Molecular Pathways

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3732</td>
<td>Molecular Pathways: Environmental Estrogens Activate Nongenomic Signaling to Developmentally Reprogram the Epigenome</td>
<td>Rebecca Lee Yean Wong and Cheryl Lyn Walker</td>
</tr>
<tr>
<td>3738</td>
<td>Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers</td>
<td>Vallerie Gordon and Shantanu Banerji</td>
</tr>
</tbody>
</table>

#### Review

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

## HUMAN CANCER BIOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3755</td>
<td>T_{H2} Cytokines from Malignant Cells Suppress T_{H1} Responses and Enforce a Global T_{H2} Bias in Leukemic Cutaneous T-cell Lymphoma</td>
<td>Emmanuela Guenova, Rei Watanabe, Jessica E. Teague, Jennifer A. Desimone, Ying Jiang, Mitra Dowlatshahi, Christoph Schlaphab, Knut Schuekel, Alain H. Rook, Marianne Tawa, David C. Fisher, Thomas S. Kupper, and Rachael A. Clark</td>
</tr>
</tbody>
</table>

## CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3796</td>
<td>Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy</td>
<td>Yi-Xiang Zhang, Jolieke G. van Oosterwijk, Ewa Sicinska, Samuel Moss, Stephen P. Remillard, Tom van Wezel, Claudia Bühnemann, Andrew B. Hassan, George D. Demetri, Judith V.M.G. Bovée, and Andrew J. Wagner</td>
</tr>
</tbody>
</table>
3808 PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Marine Knockout Models of Head and Neck Cancer

See commentary, p. 3719

3820 Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy
Emanuela Grassilli, Robert Narloch, Elena Federzoni, Leonarda Ianzano, Fabio Pisano, Roberto Giovannoni, Gabriele Romano, Laura Masiero, Biagio Eugenio Leone, Serena Bonin, Marisa Donada, Giorgio Stanta, Kristian Helin, and Marialuisa Lavitrano

3832 Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia
David P. Conrad, Jovian Tsang, Meaghan Maclean, Jean-Simon Diallo, Fabrice Le Boeuf, Chantal G. Lemay, Theresa J. Falls, Kelley A. Parato, John C. Bell, and Harold L. Atkins

3844 Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16×33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Andres Wiernik, Bree Foley, Bin Zhang, Michael R. Verneris, Erica Warlick, Michelle K. Gleason, Julie A. Ross, Xianghua Luo, Daniel J. Weisdorf, Bruce Walcheck, Daniel A. Vallera, and Jeffrey S. Miller

3856 Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2

3871 Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts
Rebecca Voltan, Paola Secchiero, Barbara Ruizi, Flavio Forni, Chiara Agostinis, Lorenzo Caruso, Maria Angela Vandelli, and Giorgio Zauli

3881 Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
Lana McClements, Anita Yakkundi, Angelos Papaspyropoulos, Hannah Harrison, Matthew P. Ablett, Puthen V. Jithesh, Hayley D. McKeen, Rachel Bennett, Christopher Donley, Adrien Kisserpfennig, Stuart McIntosh, Helen O. McCarthy, Eric O’Neill, Robert B. Clarke, and Tracy Robson

3894 USP8 Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer

IMAGING, DIAGNOSIS, PROGNOSIS

3905 Ketogenic Diets Enhance Oxidative Stress and Radio-Chemo-Therapy Responses in Lung Cancer Xenografts

3914 Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3–Selective Molecular Imaging
Quang-Dé Nguyen, Ioannis Lavdas, James Gubbins, Graham Smith, Robin Fortt, Laurence S. Carroll, Martin A. Graham, and Eric O. Aboagye

3925 Spinophilin Loss Correlates with Poor Patient Prognosis in Advanced Stages of Colon Carcinoma

3936 Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino, Anita Giobbie-Hurder, Maria Gargano, Margaret Suda, Nikhil H. Ramaiya, and F. Stephen Hodi
Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma
Wen-Wei Zhu, Jia-Jian Guo, Lei Guo, Hu-Liang Jia, Ming Zhu, Ju-Bo Zhang, Christopher A. Loffredo, Marshonna Forgues, Hua Huang, Xu-Jian Xing, Ning Ren, Qiong-Zhu Dong, Hai-Jun Zhou, Zheng-Gang Ren, Nai-Qing Zhao, Xin Wei Wang, Zhao-You Tang, Lun-Xiu Qin, and Qing Hai Ye

The Prognostic Value of MicroRNAs Varies with Patient Race/Ethnicity and Stage of Colorectal Cancer
Liselle C. Bovell, Chandrakumar Shanmugam, Balananda-Dhurjati K. Putcha, Venkat R. Katchoori, Bin Zhang, Sejong Bae, Karan P. Singh, William E. Grizzle, and Upender Manne

CANCER THERAPY: CLINICAL

Antibiotic Treatment Decreases Microbial Burden Associated with Pseudomyxoma Peritonei and Affects β-Catenin Distribution
Cristina Semino-Mora, Traci L. Testerman, Hui Liu, Jeannette M. Whitmire, Kimberley Studeman, Yali Jia, Thomas J. McAvoy, Jennifer Francis, Carol Nieroda, Armando Sardi, D. Scott Merrell, and Andre Dubois

Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma
Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey, and Jeffrey S. Weber

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens
Kimmie Ng, Josep Tabernero, Jimmy Hwang, Emilio Rajetta, Sunil Sharma, Salvatore A. Del Prete, Edward R. Arrowsmith, David P. Ryan, Michaella Sedova, Jin Jin, Kamel Malek, and Charles S. Fuchs

LETTER TO THE EDITOR

PD-L1 Expression in B-cell Lymphomas and Virus-Associated Malignancies—Letter
Mads Hald Andersen

CORRECTION

Correction: Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
About the Cover

β-catenin is a transmembrane protein that associates with junctional proteins and assists with the maintenance of cell attachment. As revealed through immunofluorescent staining, β-catenin (shown in green) localizes to the cell membranes and within the lateral junctional complex in normal appendix tissue. In contrast, tissue samples from patients with pseudomyxoma peritonei display primarily cytoplasmic staining of β-catenin and virtually no staining at the intercellular boundaries. However, antibiotic treatment of patients with pseudomyxoma peritonei results in a significant increase in β-catenin within the cell membranes, appearing to aid in the renormalization of β-catenin distribution. For details, see the article by Semino-Mora and colleagues on page 3966 of this issue.
Clinical Cancer Research

19 (14)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/19/14

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.